Six types of drug-eluting stents show the similar clinical outcomes for the treatment of ST-segment elevation myocardial infarction

Abstract

Purpose: There were no published data regarding the clinical efficacy and safety of endothelial progenitor cell capture-stents (EPC-S) compared with 1st generation (sirolimus-eluting stent, SES and paclitaxel-eluting stent, PES) and 2nd generation (zotarolimus-eluting stent, ZES and everolimus-eluting stent, EES and zotarolimus-eluting stent with biolinx polymer, ZES-BP) drug-eluting stents (DES) following primary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). We evaluated the one-year outcome of EPC capture-stents vs 5 types DES (ZES-BP, EES, ZES, SES and PES) for the primary PCI. Methods: A prospective, open-labeled, multi-center cohort was performed. The primary endpoint was major adverse cardiac event (MACE): the composite of cardiac death (CD), recurrent MI and ischemia-driven target vessel revascularization (TVR). Stent thrombosis (ST) was defined by ARC. Results: Total 1055 patients (EPC-S=80, ZES-BP=178, EES=197, ZES=203, SES=203, PES=194) who were completed more than 1 year were analyzed. 1 year MACE were 6.3%, 3.4%, 2.0%, 5.9%, 3.4% and 5.7% in EPC-S, ZES-BP, EES, ZES, SES and PES group (p=ns). Cardiac death were 5.0%, 1.0%, 2.5%, 1.5% and 1.0%, respectively (p=ns). ST were 0%, 0%, 2.0%, 2.0% and 2.0% (p=ns). View this table: Clinical outcomes at 12 months Conclusions: Campared with 1st and 2nd generation DES (SES, PES, ZES, EES and ZES-BP), EPC-S showed similar one-year clinical outcomes in terms of MACE in patients with STEMI following primary PCI.